DBV Technologies (DBVT) Operating Margin (2020 - 2026)
DBV Technologies (DBVT) reported Operating Margin of 5322.22% for Q1 2026, down 199722.0% year-over-year from N/an in Q1 2025, and up 23.8% quarter-over-quarter from 6984.65% in Q4 2025.
DBV Technologies (DBVT) Operating Margin (2020 - 2026) Analysis & Trends
DBV Technologies (DBVT) has 7 years of Operating Margin data on file, last reported at 5322.22% in Q1 2026.
- Operating Margin for Q1 2026 came in at 5322.22%, down 199722.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 2910.43% (up 32408.0% YoY), and the FY2025 annual result was 2609.23%, up 19947.0% from the prior year.
- Operating Margin advanced to 5322.22% in Q1 2026 per DBVT's latest filing, from 6984.65% in the prior quarter.
- Over five years, Operating Margin peaked at 2915.41% in Q4 2022 and troughed at 6984.65% in Q4 2025.
- A 5-year average of 2073.67% and a median of 1558.08% in 2022 frame the typical range for Operating Margin.
- The sharpest annual moves came in 2022 and 2024: Operating Margin jumped 337507 bps in 2022, then sank 453516 bps in 2024.
- A 5-year view of Operating Margin shows it stood at 2915.41% in 2022, then sank by 105 bps to 134.31% in 2023, then tumbled by 3377 bps to 4669.47% in 2024, then sank by 50 bps to 6984.65% in 2025, then gained by 24 bps to 5322.22% in 2026.
- Business Quant data shows DBVT's Operating Margin at 5322.22% in Q1 2026, 6984.65% in Q4 2025, and 1235.65% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | DBV Technologies | 6.63 Bn | 6.41 Bn | -3.90 Mn | -5,322.22% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5,322.22% |
| Dec 31, 2025 | -6,984.65% |
| Sep 30, 2025 | -1,235.65% |
| Jun 30, 2025 | -2,806.21% |
| Mar 31, 2025 | -3,325.00% |
| Dec 31, 2024 | -4,669.47% |
| Sep 30, 2024 | -2,829.10% |
| Jun 30, 2024 | -2,914.90% |
| Mar 31, 2024 | -2,029.71% |
| Dec 31, 2023 | -134.31% |
| Sep 30, 2023 | -770.24% |
| Jun 30, 2023 | -1,095.98% |
| Mar 31, 2023 | -964.68% |
| Dec 31, 2022 | 2,915.41% |
| Sep 30, 2022 | -868.85% |
| Jun 30, 2022 | -1,558.08% |
| Mar 31, 2022 | -658.72% |
| Dec 31, 2021 | -459.65% |
| Sep 30, 2021 | -1,841.87% |
| Jun 30, 2021 | -2,092.34% |